Compare GCO & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCO | OABI |
|---|---|---|
| Founded | 1924 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.2M | 277.8M |
| IPO Year | 1994 | N/A |
| Metric | GCO | OABI |
|---|---|---|
| Price | $26.98 | $1.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $31.33 | $6.67 |
| AVG Volume (30 Days) | 194.9K | ★ 311.5K |
| Earning Date | 03-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,606,898,000.00 | N/A |
| Revenue This Year | $5.42 | N/A |
| Revenue Next Year | $2.41 | $66.20 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 13.71 | N/A |
| 52 Week Low | $16.19 | $1.22 |
| 52 Week High | $38.95 | $3.52 |
| Indicator | GCO | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 42.43 | 46.29 |
| Support Level | $25.56 | $1.69 |
| Resistance Level | $29.79 | $1.75 |
| Average True Range (ATR) | 1.43 | 0.09 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 41.79 | 44.90 |
Genesco Inc. sells footwear, headwear, sports apparel, and accessories through four main segments. The Journeys Group generates the highest revenue, encompassing the Journeys, Journeys Kidz, and Little Burgundy brands, along with e-commerce and catalog sales. The Schuh Group targets teenagers and young adults aged 16 to 24, focusing on casual and athletic footwear. The Johnston & Murphy Group operates retail shops and factory stores across the United States. Finally, the Genesco Brands Group designs and sources licensed footwear for brands like Levi's, Dockers, and G.H. Bass.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.